Copyright © 2021. Inderes Oyj. All rights reserved.

Faron Pharmaceuticals

Analyytikko

Viimeisin video

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
17.9.
2021

Faron Pharmaceuticals Ltd.

("Faron")

Faron Announces Presentation of Updated MATINS Data at ESMO Showing Bexmarilimab Delivers Compelling

Antitumour Activity Across Five Different Advanced Solid Tumors

Tiedotteet
26.8.
2021

Faron Pharmaceuticals Oy

("Faron")

Faron Reports Half-Year Financials, January 1 - June 30, 2021

Significant progress made in H1 2021 including acceleration of most advanced pipeline assets - Bexmarilimab and Traumakine[Ò]

August 26, 2021 at 7:00 am BST / 9:00 am EEST

Tiedotteet
25.8.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron Pharmaceuticals Doses First Patient in Phase II/III HIBISCUS Trial of Traumakine for Treatment of Hospitalized COVID-19 Patients

Trial co-funded by US Department of Defense

Company announcement, August 25, 2021 at 9.00 AM (EEST)
Inside information

Tiedotteet
28.7.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron Pharmaceuticals to Report Half-Year Financial Results on Thursday, August 26, 2021

 

Company announcement, July 28, 2021 at 7:00 am BST / 9:00 am EEST

Tiedotteet
22.6.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Updated corporate presentation

Company announcement, 22 June 2021 at 9.00 AM (EEST)
 

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, has today published an updated corporate presentation on its website.

The presentation contains previously published Company information, views of Management and data from Faron's development programmes.

Tiedotteet
14.6.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Bexmarilimab granted key US patent

Company announcement, 14 June 2021 at 9.00 AM (EEST)
 

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the United States Patent and Trademark Office has granted a new US Patent, No. 11,046,761, with claims protecting the composition of matter of bexmarilimab. The patent will be issued on 29 June, 2021.

Tiedotteet
3.6.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

First-in-human bexmarilimab results published in Clinical Cancer Research

- Results reveal the role of Clever-1 receptor in supressing adaptive immunity

- Bexmarilimab's macrophage-targeting approach activates T-cells and drives anti-tumour immune responses in cold tumours that are not otherwise responsive to immunotherapy

Company announcement, 3 June 2021 at 9.00 AM (EET)
 

Tiedotteet
17.5.
2021

 Faron Pharmaceuticals Oy

("Faron" or the "Company")

Tiedotteet
14.5.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron secures U.S. rights to patent related to Traumakine 

Company announcement, 14 May 2021 at 9.00 AM (EEST)
 

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that it has signed a sub-license agreement for the rights to U.S. patent US9,376,478, which currently extends to 2033.

Tiedotteet
10.5.
2021

TR-1: Standard form for notification of major holdings

[][][][][][][][]
NOTIFICATION OF
MAJOR HOLDINGS
(to
be sent to the
relevant issuer
and
to the FCA in
Microsoft Word
format
if possible)[i]

Faron Pharmaceuticals

ipo